ALNYLAM IS LEADING THE RNAi REVOLUTION™

Andrew Fire and Craig Mello publish paper describing the discovery of RNA interference

Phillip Sharp’s 1999 Genes & Development perspective sparks collaboration and experimentation among Alnylam’s founders

Alnylam is founded on June 14 by Phillip Sharp, David Bartel, Thomas Tuschl, Paul Schimmel and Phillip Zamore

Tuschl 1 and 2 patents in-licensed from MIT, Max Planck and Whitehead

Alnylam IPO and listing on the Nasdaq exchange

First RNAi clinical program initiated (ALN-RSV01)

Discovery of RNAi awarded the Nobel Prize in Medicine and Physiology

Zimmerman et. al., Nature paper conclusively demonstrates the gene-silencing effect of RNAi therapeutics in mammals for the first time

Alnylam 5x15 five-year strategy launched

First human POC for RNAi
(ALN-TTR01 and ALN-TTR02)

Alnylam's first manufacturing facility opens in Cambridge, Massachusetts (Alewife)

First NEJM paper published on the safety and efficacy of patisiran

First human POC for GalNAc conjugates as a delivery mechanism

First Alnylam international office opens in Maidenhead, UK

Alnylam 2020 five-year strategy launched

Groundbreaking for Norton Manufacturing Facility

First positive Phase 3 Study for Alnylam and an RNAi therapeutic
(APOLLO study for patisiran)

Positive Topline Results from ENVISION Phase 3 Study of Givosiran

ONPATTRO®  approved in the US and EU. First-ever approved RNAi therapeutic, and Alnylam’s first commercial medicine

Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran

Positive Complete Results from ORION-11 Phase 3 Study of Inclisiran (licensed to Medicines Company)

Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran

OXLUMO®  (lumasiran) approved in US and EU

Leqvio® (inclisiran) approved in the US and EU (licensed to Novartis)

Alnylam P⁵x25 five-year strategy launched

GIVLAARI® (givosiran) approved in the US and EU

AMVUTTRA® (vutrisiran) approved in the US and EU

Alnylam Celebrates 20th Anniversary

Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with
ATTR-CM

First POC for targeted delivery of RNAi therapeutic to CNS (ALN-APP)

First $1B annual in net product revenue

Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR-CM